

INTRABIOTICS PHARMACEUTICALS INC /DE
Form SC 13D/A
May 23, 2003

OMB APPROVAL

OMB Number 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response 11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*

INTRABIOTICS PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, \$.001 par value

(Title of Class of Securities)

46116T 10 0

(CUSIP Number)

Kevin C. Tang
Tang Capital Management, LLC
4401 Eastgate Mall
San Diego, CA 92121
(858) 200-3831

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

May 14, 2003

(Date of Event which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [] .

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

CUSIP No. 46116T 10 0

1. Name of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Tang Capital Partners, LP

2. Check the Appropriate Box If a Member of a Group (See Instructions)
(a)
(b) Joint-Filing

3. SEC Use Only

4. Source of Funds (See Instructions)
WC

5. Check If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)

6. Citizenship or Place of Organization
United States

NUMBER OF 7. Sole Voting Power
SHARES 1,471,041*

BENEFICIALLY 8. Shared Voting Power
OWNED BY 0
EACH

REPORTING 9. Sole Dispositive Power
PERSON 1,471,041*
WITH

10. Shared Dispositive Power
0

11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,471,041*

12. Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)

13. Percent of Class Represented by Amount in Row (11)
32.3%

14. Type of Reporting Person (See Instructions)
PN

* Represents 192,579 shares of common stock, shares of preferred stock convertible into 852,308 shares of common stock, and warrants to purchase up to 426,154 shares of common stock.

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

CUSIP No. 46116T 10 0

1. Name of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Tang Capital Management, LLC

2. Check the Appropriate Box If a Member of a Group (See Instructions)
(a)
(b) Joint-Filing

3. SEC Use Only

4. Source of Funds (See Instructions)
WC

5. Check If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)

6. Citizenship or Place of Organization
United States

	7. Sole Voting Power
NUMBER OF	1,471,041*
SHARES	-----
BENEFICIALLY	8. Shared Voting Power
OWNED BY	0
EACH	-----
REPORTING	9. Sole Dispositive Power
PERSON	1,471,041*
WITH	-----
	10. Shared Dispositive Power
	0

11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,471,041*

12. Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)

13. Percent of Class Represented by Amount in Row (11)
32.3%

14. Type of Reporting Person (See Instructions)
OO

* Represents 192,579 shares of common stock, shares of preferred stock convertible into 852,308 shares of common stock, and warrants to purchase up to 426,154 shares of common stock.

CUSIP No. 46116T 10 0

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

1. Name of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Kevin C. Tang

2. Check the Appropriate Box If a Member of a Group (See Instructions)
(a)
(b) Joint-Filing

3. SEC Use Only

4. Source of Funds (See Instructions)
WC

5. Check If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)

6. Citizenship or Place of Organization
United States

- | | | |
|--|------------------------------|------------|
| NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH | 7. Sole Voting Power | 1,471,041* |
| | 8. Shared Voting Power | 0 |
| | 9. Sole Dispositive Power | 1,471,041* |
| | 10. Shared Dispositive Power | 0 |

11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,471,041*

12. Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)

13. Percent of Class Represented by Amount in Row (11)
32.3%

14. Type of Reporting Person (See Instructions)
IN

* Represents 192,579 shares of common stock, shares of preferred stock convertible into 852,308 shares of common stock, and warrants to purchase up to 426,154 shares of common stock.

CUSIP No. 46116T 10 0

1. Name of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Oscar L. Tang

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

2. Check the Appropriate Box If a Member of a Group (See Instructions)

- (a)
(b) Joint-Filing

3. SEC Use Only

4. Source of Funds (See Instructions)
PF

5. Check If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)

6. Citizenship or Place of Organization
United States

	7. Sole Voting Power
NUMBER OF SHARES	23,408
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8. Shared Voting Power
	9,539
	9. Sole Dispositive Power
	23,408
	10. Shared Dispositive Power
	9,539

11. Aggregate Amount Beneficially Owned by Each Reporting Person
32,947

12. Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)

13. Percent of Class Represented by Amount in Row (11)
1.0%

14. Type of Reporting Person (See Instructions)
IN

ITEM 1. SECURITY AND ISSUER

This Amendment No. 1 to Schedule 13D ("Amendment No. 1") is being filed as an amendment to the initial statement on Schedule 13D relating to the common stock \$.001 par value per share of IntraBiotics Pharmaceuticals, Inc., a Delaware Corporation (the "Issuer" or "IBPI" herein), as filed with the Securities and Exchange Commission (the "SEC") on May 1, 2003. The principal executive offices of the issuer are located at 2483 East Bayshore Road, Suite 100, Palo Alto, CA 94303.

The Schedule 13D is hereby further amended and supplemented as follows:

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

The funds used to purchase the securities referenced in Item 5 of this Amendment No. 1 were from working capital of Tang Capital Partners, LP. No

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

funds used to acquire the issuer's securities by the reporting persons were borrowed or otherwise obtained.

ITEM 4. PURPOSE OF TRANSACTION

The securities purchased by Tang Capital Partners, LP referenced in Item 5 of this Amendment No. 1 were purchased on the open market for investment purposes based on price and favorable market conditions. The reporting persons may dispose of issuer securities or purchase issuer securities for investment purposes based on available price and other general market conditions for the securities and in compliance with the issuer's internal trading restrictions applicable to its directors (by virtue of the fact that Kevin C. Tang is a director of the issuer). Except as may arise in connection with the normal execution of Mr. Tang's position as a director, or as provided in this paragraph, none of the persons filing this statement has any present plans or proposals which relate to or would result in (a) the acquisition by any person of additional securities of the issuer (other than the acquisition of Common Stock upon conversion of Series A Preferred Stock or exercise of Warrants held by Tang Capital Partners, LP), or the disposition of securities of the issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the issuer or any of its subsidiaries; (d) any change in the present board of directors or management of the issuer (other than the designation of an additional Series A Preferred Stockholder representative to the board as described in the Schedule 13D), including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the issuer; (f) any other material change in the issuer's business or corporate structure; (g) changes in the issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person; (h) causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to any of those enumerated above.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Item 5 of the Schedule 13D is amended and restated in its entirety as follows:

(a) The aggregate number and percentage of securities to which this Schedule 13D relates is 1,503,988 shares, representing approximately 33.07% of the 3,269,168 shares of Common Stock outstanding as reported by the issuer in its Definitive Proxy Statement filed with the Securities and Exchange Commission on April 30, 2003 (and taking into account in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, a total of 852,308 shares of Common Stock issuable upon conversion of Series A Preferred Stock held as described herein and 426,154 shares of Common Stock issuable upon exercise of the Warrants held as described herein.) The reporting persons beneficially own the securities set forth below:

Name	Shares	% of Class
Tang Capital Partners, LP	1,471,041	32.3%
Tang Capital Management, LLC	1,471,041	32.3%
Kevin C. Tang	1,471,041	32.3%
Oscar L. Tang	32,947	1.0%

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

(b) Number of shares to which such person has:

(i) Sole power to vote or direct the vote:

Tang Capital Partners, LP	1,471,041 shares
Tang Capital Management, LLC	1,471,041 shares
Kevin C. Tang	1,471,041 shares
Oscar L. Tang	23,408 shares

(ii) Shared power to vote or direct the vote:

Tang Capital Partners, LP	0 shares
Tang Capital Management, LLC	0 shares
Kevin C. Tang	0 shares
Oscar L. Tang	9,539 shares

(iii) Sole power to dispose or direct the disposition of:

Tang Capital Partners, LP	1,471,041 shares
Tang Capital Management, LLC	1,471,041 shares
Kevin C. Tang	1,471,041 shares
Oscar L. Tang	23,408 shares

(iv) Shared power to dispose or direct the disposition of:

Tang Capital Partners, LP	0 shares
Tang Capital Management, LLC	0 shares
Kevin C. Tang	0 shares
Oscar L. Tang	9,539 shares

Oscar L. Tang's shares' voting and dispositive powers are through an investment advisor or trustee relationship for various family members.

(c) Transactions effected since the filing of Schedule 13D filed with the SEC on May 1, 2003:

The following open market purchases were effected by Tang Capital Partners, LP:

TRADE DATE	NO. SHARES	PRICE
05/12/03	7,400	\$1.8564
05/14/03	30,000	\$1.7969
05/15/03	15,000	\$1.7672
05/16/03	900	\$1.7788

There were no other purchases by any of the reporting persons since May 1, 2003.

(d) Not applicable.

(e) Not applicable.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

Exhibit A Agreement of Joint Filing, dated May 21, 2003 (filed as Exhibit A with an earlier filed version of this Schedule 13D.)

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

TANG CAPITAL PARTNERS, LP
By: Tang Capital Management, LLC

By: /s/ Kevin C. Tang

Kevin C. Tang, Manager

TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin C. Tang

Kevin C. Tang, Manager

/s/ Kevin C. Tang

KEVIN C. TANG

/s/ Oscar L. Tang

OSCAR L. TANG

ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)